Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Gastrointestinal Cancers

26 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

Esophageal

VICCGI1012

03/05/2010

Foregut Mircobiome in Development of Esophageal Adenocarcinoma (Clinical Sampling Protocol)

Diagnostic

Liver

VICCGI1343

02/06/2014

Multi-Parametric 3 Tesla Magnetic Resonance Imaging (MRI) of Response to Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma (HCC)

Diagnostic

VICCGI0283

06/01/2002

Novel Gastrointestinal Cancer Markers in Tissue and Biofluids

Other

Colon
Rectum

VICCGI99003

08/01/2010

Personalized Prevention of Colorectal Cancer

Other

Colon
Rectal

VICCGI0721

01/09/2007

Vanderbilt Hereditary Colorectal Cancer Registry

Other

Liver
Neuroendocrine

VICCGI0372

10/01/2003

Outcomes Following Image-Guided Therapy for Hepatic Malignancies.

Prevention

Colon

GIS0820-M

07/09/2013

A double blind placebo controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colon ca in patients with stage 0-III colon ca; phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac

Supportive Care

Colon
Rectal

VICCGI1416

08/19/2014

Programs to Support You During Chemotherapy (Pro-You)

Supportive Care

Breast
Colon
Lung
Prostate
Rectal

VICCREACH1341

09/05/2013

Using a Tailored Navigation Intervention to Prepare Patients and Their Support Person for the Journey at Time of Cancer Diagnosis and at Transition into Survivorship

Treatment

Pancreatic

VICCGI1405

08/07/2014

A Phase 3, Multicenter, Open-Label, Randomized Study of nab?-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Treatment

Colon

VICCGI13104

08/06/2014

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer

Treatment

Esophageal
Gastric/Gastroesophageal

VICCGI13114

08/04/2014

A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors

Treatment

Colon
Rectal

VICCGI13101

06/24/2014

Randomized, Double-Blind, Phase II Trial of Vitamin D Supplementation in Participants with Previously Untreated Metastatic Colorectal Cancer

Treatment

Pancreatic

VICCGI13100

06/10/2014

A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (with Cyclophosphamide) and CRS-207 Compared to Chemotherapy or to CRS-207 Alone in Adults with Previously-Treated Metastatic Pancreatic Adenocarcinoma

Treatment

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Treatment

Esophageal
Gastric/Gastroesophageal
Lung
Non Small Cell
Pancreatic

VICCPHI1360

04/22/2014

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination with Chemotherapy in Subjects with Advanced Solid Tumors

Treatment

Breast
Colon
Lung
Ovarian
Pancreatic
Prostate
Rectal

VICCPHI1394

04/17/2014

A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancer

Treatment

Breast
Gastric/Gastroesophageal
Lung
Pancreatic

VICCPHI1359

12/03/2013

A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab combined with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Treatment

Colon
Rectal

ECOGGIS0820

09/03/2013

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

Treatment

Esophageal
Gastric/Gastroesophageal

VICCGI1306

07/11/2013

Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel with Trastuzumab in Patients with HER2 Positive Carinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy

Treatment

Colon
Rectum

VICCPHI1314

06/25/2013

A Phase I/II Study of Once or Twice Weekly IMMU-130 (hMN-14- SN38, Antibody-Drug Conjugate) in Patients with Colorectal Cancer

Treatment

Pancreatic

VICCGI1173

07/31/2012

A Phase 1 Study of Gemcitabine, Dasatinib and Erlotinib in Patients with Advanced Pancreatic Carcinoma

Treatment

Adrenocortical
Bladder
Breast
Cervical
Colon
Dermatologic
Esophageal
GIST
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Liver
Lung
Multiple Myeloma
Neuroendocrine
Ovarian
Pancreatic
Prostate
Rectal
Sarcoma
Small Cell
Uterine

VICCMD1188

06/08/2012

An Open-Label, Phase II Study of Vemurafenib in Patients with BRAF V600 Mutation-Positive Cancers

Treatment

Liver

CTSUGI80702-M

05/05/2011

A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or placebo for patients with Resected Stage III Colon Cancer

Treatment

Liver

CTSUGIC80802-M

12/07/2010

Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Treatment

GIST

VICCPHI0958

02/05/2010

A Phase 1 Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of PLX3397 in Patients with Advanced, Incurable, Solid Tumors in which the Target Kinases Are Linked to Disease Pathophysiology